# Early add-on Vildagliptin in Patients With Type 2 Diabetes Inadequately Controlled by Metformin

> **NCT01766778** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 117 (actual)

## Conditions studied

- Type-2 Diabetes Mellitus

## Interventions

- **DRUG:** LAF237 (vildagliptin)
- **DRUG:** Metformin

## Key facts

- **NCT ID:** NCT01766778
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05-13
- **Primary completion:** 2015-10-22
- **Final completion:** 2015-10-22
- **Target enrollment:** 117 (ACTUAL)
- **Last updated:** 2017-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01766778

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01766778, "Early add-on Vildagliptin in Patients With Type 2 Diabetes Inadequately Controlled by Metformin". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01766778. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*